Paradigm Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Paradigm Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,700	Closed	-$354K	–	494
2017 Q2	$354K	Sell	5,700 -5,900	-51%	-$355K	0.07%	284
2017 Q1	$786K	Buy	11,600 +10,000	+625%	+$762K	0.15%	155
2016 Q4	$112K	Hold	1,600	–	–	0.02%	381
2016 Q3	$114K	Sell	1,600 -150	-9%	-$9.57K	0.02%	389
2016 Q2	$85.6K	Sell	1,750 -7,300	-81%	-$472K	0.01%	487
2016 Q1	$573K	Sell	9,050 -400	-4%	-$26.2K	0.11%	199
2015 Q4	$1.06M	Buy	9,450 +2,650	+39%	+$265K	0.18%	111
2015 Q3	$655K	Sell	6,800 -34,100	-83%	-$3.9M	0.09%	241
2015 Q2	$4.19M	Hold	40,900	–	–	0.47%	78
2015 Q1	$2.54M	Buy	+40,900	New	+$2.27M	0.28%	122

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Paradigm Asset Management's RARE Position: Q3 2017 in Review

Paradigm Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2017, closing a stake of 5,700 shares — an estimated $354K sold.

Paradigm Asset Management first reported a position in RARE in Q1 2015 and held it in 10 quarters. The position peaked at $4.19M in Q2 2015. 154 funds tracked by Wall St. Rank hold RARE as of Q3 2017.

Paradigm Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2017 after selling out during the quarter.
Paradigm Asset Management sold 5,700 Ultragenyx Pharmaceutical shares in Q3 2017, an estimated $354K.
Paradigm Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and held it in 10 quarters.
Paradigm Asset Management's Ultragenyx Pharmaceutical position peaked at $4.19M in Q2 2015.
154 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.